Table I.

Baseline characteristics and therapies of the study population

	10-year survivors N=186	10-year non-survivors N=647	P
Age, years; median (range)	57 (49–64)	64 (57–71)	<0.001
Male sex	52%	64%	0.003
Single organ	47%	27%	<0.001
Heart involvement	46%	86%	<0.001
Kidney involvement	75%	57%	<0.001
Liver involvement	18%	26%	0.02
GI involvement	15%	18%	0.31
Nerve involvement	10%	20%	<0.001
Mayo 2004 stage I/II/III/IIIB (%)	35/46/15/4	11/33/30/26	<0.001
Mayo 2012 stage I/II/III/IV (%)	41/37/13/9	12/19/30/39	<0.001
SBP <100 mmHg	12%	25%	<0.001
Seen within 30 days from diagnosis	47%	65%	<0.001
Lambda light chain	76%	76%	0.98
BMPC	7 (5–10)	10 (6–18)	<0.001
dFLC	13 (7–33)	29 (14–73)	<0.001
S-phase greater than 0%#	33%	44%	0.01
Significant immunoparesis^ (negative ARD)	27%	42%	<0.001
FISH abnormalities*
t(11;14)	56%	52%	0.65
chromosome 13 abnormalities	36%	34%	0.76
Trisomies	8%	27%	0.003
First-line therapy&
Standard therapies
MDex	35 (19%)	188 (35%)
Bortezomib-based	3 (1.5%)	8 (1.5%)	<0.001
IMiD-based	5 (2.5%)	19 (3.5%)
Dexamethasone/MP	11 (6%)	189 (35%)
ASCT	132 (71%)	134 (25%)

^#Available for 69% of the patients

^{^}Available for 84% of the patients. ARD is a quantifiable measure of immunoparesis, where a negative result is consistent with more pronounced immunoparesis.(Muchtar, et al 2017b)

^*Available for 19% of the patients

^&In the 10-year non-survival cohort 78 patients did not receive therapy, 27 patients had unconfirmed treatment and 4 received other forms of therapy than listed in the table.

Abbreviations: ARD: average relative difference; ASCT: autologous stem cell transplantation; BMPC: bone marrow plasma cells; dFLC: difference between involved to uninvolved light chains; FISH: fluorescence in situ hybridisation; GI: gastrointestinal; IMiD: immunomodulatory drug; MDex: melphalan-dexamethasone; MP: melphalan-prednisone; SBP: systolic blood pressure.